Takeda Pharmaceutical Company Limited
4502
Rank in Stocks
#375
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Share Price
$40.45
Market Cap
$64.36B
Change (1 day)
1.19%
Change (1 year)
43.11%
Country
JP
Trade Takeda Pharmaceutical Company Limited (4502)
Category
Healthcare
Revenue for Takeda Pharmaceutical Company Limited (4502)
Revenue in Oct 2026 TTM: 0
According to Takeda Pharmaceutical Company Limited latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Takeda Pharmaceutical Company Limited from 2026 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| - | - |
CN
|
|
| $6.61B | - |
IN
|
